206 related articles for article (PubMed ID: 26851650)
21. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
22. Serum HE4 as a diagnostic and prognostic marker for lung cancer.
Iwahori K; Suzuki H; Kishi Y; Fujii Y; Uehara R; Okamoto N; Kobayashi M; Hirashima T; Kawase I; Naka T
Tumour Biol; 2012 Aug; 33(4):1141-9. PubMed ID: 22373583
[TBL] [Abstract][Full Text] [Related]
23. Value of serum marker HE4 in pulmonary carcinoma diagnosis.
Tang QF; Zhou ZW; Ji HB; Pan WH; Sun MZ
Int J Clin Exp Med; 2015; 8(10):19014-21. PubMed ID: 26770527
[TBL] [Abstract][Full Text] [Related]
24. Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay.
Muley T; Ebert W; Stieber P; Raith H; Holdenrieder S; Nagel D; Fürst H; Roth HJ; Luthe H; Blijenberg BG; Gurr E; Uhl W; von Pawel J; Drings P
Clin Chem Lab Med; 2003 Jan; 41(1):95-103. PubMed ID: 12636057
[TBL] [Abstract][Full Text] [Related]
25. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.
Muley T; He Y; Rolny V; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Meister M; Herth FJ; Dayyani F
Lung Cancer; 2019 Apr; 130():194-200. PubMed ID: 30885344
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
29. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
30. Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.
Lou E; Johnson M; Sima C; Gonzalez-Espinoza R; Fleisher M; Kris MG; Azzoli CG
Cancer Biomark; 2014; 14(4):207-14. PubMed ID: 24934363
[TBL] [Abstract][Full Text] [Related]
31. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
32. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
33. Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer.
Park J; Yang JS; Jung G; Woo HI; Park HD; Kim JW; Huh W; Ko JW; Kim H; Cho JY; Lee SY
J Proteomics; 2013 Dec; 94():302-10. PubMed ID: 24120528
[TBL] [Abstract][Full Text] [Related]
34. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.
Molina R; Marrades RM; Augé JM; Escudero JM; Viñolas N; Reguart N; Ramirez J; Filella X; Molins L; Agustí A
Am J Respir Crit Care Med; 2016 Feb; 193(4):427-37. PubMed ID: 26465739
[TBL] [Abstract][Full Text] [Related]
35. [Clinical utility of serum tumor markers in lung cancer].
Zhao X; Wang M
Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):286-91. PubMed ID: 21426676
[TBL] [Abstract][Full Text] [Related]
36. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
37. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
38. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of cerebrospinal fluid human epididymis protein 4 for leptomeningeal metastasis in lung adenocarcinoma.
Li X; Chen K; Li J; Tang X; Ruan H; Guan M
Front Immunol; 2024; 15():1339914. PubMed ID: 38304432
[TBL] [Abstract][Full Text] [Related]
40. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
